Terms: = Ovarian cancer AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2 AND Clinical Outcome
21 results:
1. kras mutation in primary ovarian serous borderline tumors correlates with tumor recurrence.
McHenry A; Rottmann DA; Buza N; Hui P
Virchows Arch; 2023 Jul; 483(1):71-79. PubMed ID: 37219599
[TBL] [Abstract] [Full Text] [Related]
2. Whole exome sequencing of low grade serous ovarian carcinoma identifies genomic events associated with clinical outcome.
Thomson JP; Hollis RL; van Baal J; Ilenkovan N; Churchman M; van de Vijver K; Dijk F; Meynert AM; Bartos C; Rye T; Croy I; Diana P; van Gent M; Creedon H; Nirsimloo R; Nussey F; Lok C; Herrington CS; Gourley C
Gynecol Oncol; 2023 Jul; 174():157-166. PubMed ID: 37207500
[TBL] [Abstract] [Full Text] [Related]
3. Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome.
Hollis RL; Thomson JP; Stanley B; Churchman M; Meynert AM; Rye T; Bartos C; Iida Y; Croy I; Mackean M; Nussey F; Okamoto A; Semple CA; Gourley C; Herrington CS
Nat Commun; 2020 Oct; 11(1):4995. PubMed ID: 33020491
[TBL] [Abstract] [Full Text] [Related]
4. Molecular diagnosis in type I epithelial ovarian cancer.
Sadłecki P; Walentowicz-Sadłecka M; Grabiec M
Ginekol Pol; 2017; 88(12):692-697. PubMed ID: 29303228
[TBL] [Abstract] [Full Text] [Related]
5. kras mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome.
Zuo T; Wong S; Buza N; Hui P
Mod Pathol; 2018 Feb; 31(2):350-357. PubMed ID: 29027536
[TBL] [Abstract] [Full Text] [Related]
6. Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum.
Gershenson DM; Sun CC; Wong KK
Br J Cancer; 2015 Nov; 113(9):1254-8. PubMed ID: 26484411
[TBL] [Abstract] [Full Text] [Related]
7. No clinical utility of kras variant rs61764370 for ovarian or breast cancer.
; Hollestelle A; van der Baan FH; Berchuck A; Johnatty SE; Aben KK; Agnarsson BA; Aittomäki K; Alducci E; Andrulis IL; Anton-Culver H; Antonenkova NN; Antoniou AC; Apicella C; Arndt V; Arnold N; Arun BK; Arver B; Ashworth A; ; Baglietto L; Balleine R; Bandera EV; Barrowdale D; Bean YT; Beckmann L; Beckmann MW; Benitez J; Berger A; Berger R; Beuselinck B; Bisogna M; Bjorge L; Blomqvist C; Bogdanova NV; Bojesen A; Bojesen SE; Bolla MK; Bonanni B; Brand JS; Brauch H; ; Brenner H; Brinton L; Brooks-Wilson A; Bruinsma F; Brunet J; Brüning T; Budzilowska A; Bunker CH; Burwinkel B; Butzow R; Buys SS; Caligo MA; Campbell I; Carter J; Chang-Claude J; Chanock SJ; Claes KBM; Collée JM; Cook LS; Couch FJ; Cox A; Cramer D; Cross SS; Cunningham JM; Cybulski C; Czene K; Damiola F; Dansonka-Mieszkowska A; Darabi H; de la Hoya M; deFazio A; Dennis J; Devilee P; Dicks EM; Diez O; Doherty JA; Domchek SM; Dorfling CM; Dörk T; Silva IDS; du Bois A; Dumont M; Dunning AM; Duran M; Easton DF; Eccles D; Edwards RP; Ehrencrona H; Ejlertsen B; Ekici AB; Ellis SD; ; Engel C; Eriksson M; Fasching PA; Feliubadalo L; Figueroa J; Flesch-Janys D; Fletcher O; Fontaine A; Fortuzzi S; Fostira F; Fridley BL; Friebel T; Friedman E; Friel G; Frost D; Garber J; García-Closas M; Gayther SA; ; ; Gentry-Maharaj A; Gerdes AM; Giles GG; Glasspool R; Glendon G; Godwin AK; Goodman MT; Gore M; Greene MH; Grip M; Gronwald J; Gschwantler Kaulich D; Guénel P; Guzman SR; Haeberle L; Haiman CA; Hall P; Halverson SL; Hamann U; Hansen TVO; Harter P; Hartikainen JM; Healey S; ; Hein A; Heitz F; Henderson BE; Herzog J; T Hildebrandt MA; Høgdall CK; Høgdall E; Hogervorst FBL; Hopper JL; Humphreys K; Huzarski T; Imyanitov EN; Isaacs C; Jakubowska A; Janavicius R; Jaworska K; Jensen A; Jensen UB; Johnson N; Jukkola-Vuorinen A; Kabisch M; Karlan BY; Kataja V; Kauff N; ; Kelemen LE; Kerin MJ; Kiemeney LA; Kjaer SK; Knight JA; Knol-Bout JP; Konstantopoulou I; Kosma VM; Krakstad C; Kristensen V; Kuchenbaecker KB; Kupryjanczyk J; Laitman Y; Lambrechts D; Lambrechts S; Larson MC; Lasa A; Laurent-Puig P; Lazaro C; Le ND; Le Marchand L; Leminen A; Lester J; Levine DA; Li J; Liang D; Lindblom A; Lindor N; Lissowska J; Long J; Lu KH; Lubinski J; Lundvall L; Lurie G; Mai PL; Mannermaa A; Margolin S; Mariette F; Marme F; Martens JWM; Massuger LFAG; Maugard C; Mazoyer S; McGuffog L; McGuire V; McLean C; McNeish I; Meindl A; Menegaux F; Menéndez P; Menkiszak J; Menon U; Mensenkamp AR; Miller N; Milne RL; Modugno F; Montagna M; Moysich KB; Müller H; Mulligan AM; Muranen TA; Narod SA; Nathanson KL; Ness RB; Neuhausen SL; Nevanlinna H; Neven P; Nielsen FC; Nielsen SF; Nordestgaard BG; Nussbaum RL; Odunsi K; Offit K; Olah E; Olopade OI; Olson JE; Olson SH; Oosterwijk JC; Orlow I; Orr N; Orsulic S; Osorio A; Ottini L; Paul J; Pearce CL; Pedersen IS; Peissel B; Pejovic T; Pelttari LM; Perkins J; Permuth-Wey J; Peterlongo P; Peto J; Phelan CM; Phillips KA; Piedmonte M; Pike MC; Platte R; Plisiecka-Halasa J; Poole EM; Poppe B; Pylkäs K; Radice P; Ramus SJ; Rebbeck TR; Reed MWR; Rennert G; Risch HA; Robson M; Rodriguez GC; Romero A; Rossing MA; Rothstein JH; Rudolph A; Runnebaum I; Salani R; Salvesen HB; Sawyer EJ; Schildkraut JM; Schmidt MK; Schmutzler RK; Schneeweiss A; Schoemaker MJ; Schrauder MG; Schumacher F; Schwaab I; Scuvera G; Sellers TA; Severi G; Seynaeve CM; Shah M; Shrubsole M; Siddiqui N; Sieh W; Simard J; Singer CF; Sinilnikova OM; Smeets D; Sohn C; Soller M; Song H; Soucy P; Southey MC; Stegmaier C; Stoppa-Lyonnet D; Sucheston L; ; Swerdlow A; Tangen IL; Tea MK; Teixeira MR; Terry KL; Terry MB; Thomassen M; Thompson PJ; Tihomirova L; Tischkowitz M; Toland AE; Tollenaar RAEM; Tomlinson I; Torres D; Truong T; Tsimiklis H; Tung N; Tworoger SS; Tyrer JP; Vachon CM; Van 't Veer LJ; van Altena AM; Van Asperen CJ; van den Berg D; van den Ouweland AMW; van Doorn HC; Van Nieuwenhuysen E; van Rensburg EJ; Vergote I; Verhoef S; Vierkant RA; Vijai J; Vitonis AF; von Wachenfeldt A; Walsh C; Wang Q; Wang-Gohrke S; Wappenschmidt B; Weischer M; Weitzel JN; Weltens C; Wentzensen N; Whittemore AS; Wilkens LR; Winqvist R; Wu AH; Wu X; Yang HP; Zaffaroni D; Pilar Zamora M; Zheng W; Ziogas A; Chenevix-Trench G; Pharoah PDP; Rookus MA; Hooning MJ; Goode EL
Gynecol Oncol; 2016 May; 141(2):386-401. PubMed ID: 25940428
[TBL] [Abstract] [Full Text] [Related]
8. Mutation profile and clinical outcome of mixed endometrioid-serous endometrial carcinomas are different from that of pure endometrioid or serous carcinomas.
Coenegrachts L; Garcia-Dios DA; Depreeuw J; Santacana M; Gatius S; Zikan M; Moerman P; Verbist L; Lambrechts D; Matias-Guiu X; Amant F
Virchows Arch; 2015 Apr; 466(4):415-22. PubMed ID: 25677978
[TBL] [Abstract] [Full Text] [Related]
9. kras, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants.
Heublein S; Grasse K; Hessel H; Burges A; Lenhard M; Engel J; Kirchner T; Jeschke U; Mayr D
BMC Cancer; 2013 Oct; 13():483. PubMed ID: 24139521
[TBL] [Abstract] [Full Text] [Related]
10. Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology.
Ogino S; Lochhead P; Giovannucci E; Meyerhardt JA; Fuchs CS; Chan AT
Oncogene; 2014 Jun; 33(23):2949-55. PubMed ID: 23792451
[TBL] [Abstract] [Full Text] [Related]
11. ovarian cancer : making its own rules-again.
Kohn EC; Hurteau J
Cancer; 2013 Feb; 119(3):474-6. PubMed ID: 23233093
[TBL] [Abstract] [Full Text] [Related]
12. Histopathologic features of ovarian borderline tumors are not predictive of clinical outcome.
Avril S; Hahn E; Specht K; Hauptmann S; Höss C; Kiechle M; Höfler H; Schmalfeldt B
Gynecol Oncol; 2012 Dec; 127(3):516-24. PubMed ID: 23000388
[TBL] [Abstract] [Full Text] [Related]
13. PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer.
Urick ME; Rudd ML; Godwin AK; Sgroi D; Merino M; Bell DW
Cancer Res; 2011 Jun; 71(12):4061-7. PubMed ID: 21478295
[TBL] [Abstract] [Full Text] [Related]
14. Clinicopathological and molecular characterization of colorectal micropapillary carcinoma.
Verdú M; Román R; Calvo M; Rodón N; García B; González M; Vidal A; Puig X
Mod Pathol; 2011 May; 24(5):729-38. PubMed ID: 21336262
[TBL] [Abstract] [Full Text] [Related]
15. Tissue and serum biomarkers as prognostic variables in endometrioid-type endometrial cancer.
Gadducci A; Cosio S; Genazzani AR
Crit Rev Oncol Hematol; 2011 Nov; 80(2):181-92. PubMed ID: 21134766
[TBL] [Abstract] [Full Text] [Related]
16. BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.
Wong KK; Tsang YT; Deavers MT; Mok SC; Zu Z; Sun C; Malpica A; Wolf JK; Lu KH; Gershenson DM
Am J Pathol; 2010 Oct; 177(4):1611-7. PubMed ID: 20802181
[TBL] [Abstract] [Full Text] [Related]
17. Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis.
Ayhan A; Kurman RJ; Yemelyanova A; Vang R; Logani S; Seidman JD; Shih IeM
Am J Surg Pathol; 2009 Aug; 33(8):1220-4. PubMed ID: 19461510
[TBL] [Abstract] [Full Text] [Related]
18. Novel molecular profiles of endometrial cancer-new light through old windows.
Doll A; Abal M; Rigau M; Monge M; Gonzalez M; Demajo S; Colás E; Llauradó M; Alazzouzi H; Planagumá J; Lohmann MA; Garcia J; Castellvi S; Ramon y Cajal J; Gil-Moreno A; Xercavins J; Alameda F; Reventós J
J Steroid Biochem Mol Biol; 2008 Feb; 108(3-5):221-9. PubMed ID: 18061438
[TBL] [Abstract] [Full Text] [Related]
19. Molecular pathology of endometrial carcinoma: transcriptional signature in endometrioid tumors.
Abal M; Planaguma J; Gil-Moreno A; Monge M; Gonzalez M; Baro T; Garcia A; Castellvi J; Ramon Y Cajal S; Xercavins J; Alameda F; Reventos J
Histol Histopathol; 2006 Feb; 21(2):197-204. PubMed ID: 16329044
[TBL] [Abstract] [Full Text] [Related]
20. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
[TBL] [Abstract] [Full Text] [Related]
[Next]
